BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K
BioLife Solutions, Inc. (Nasdaq: BLFS) announced an additional delay in filing its Annual Report on Form 10-K for the year ended December 31, 2021. The CFO, Troy Wichterman, stated that they are working diligently to complete the report, aiming to file it by March 31, 2022. This delay raises concerns about compliance with regulatory obligations. BioLife Solutions specializes in bioproduction products and services for cell and gene therapies and broader biopharma markets.
- None.
- Delay in filing Form 10-K raises regulatory compliance concerns.
BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the "Form 10-K").
Troy Wichterman, Chief Financial Officer, stated, "We are working diligently to complete our Form 10-K and intend to file the Form 10-K no later than March 31, 2022".
About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.
Cautions Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the Company's intention to file its Form 10-K no later than March 31, 2022 and other statements about the Company's plans, objectives, expectations, beliefs and intentions and other statements including words such as "hope," "anticipate," "may," "believe," "expect," "intend," "will," "should," "plan," "estimate," "predict," "continue" and "potential" or the negative of these terms or other comparable terminology. The forward-looking statements herein represent the judgment of the Company, as of the date of this release, and the Company disclaims any intent or obligation to update forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those currently anticipated. This press release should be read in conjunction with the information included in the Company's other press releases, reports and other filings with the SEC and on the SEC website, www.sec.gov. Understanding the information contained in these filings is important in order to fully understand the Company's reported financial results and our business outlook for future periods. Actual results may differ materially from the results anticipated in the forward-looking statements and the assumptions and estimates used as a basis for the forward-looking statements.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-announces-additional-delay-in-filing-of-annual-report-on-form-10-k-301504834.html
SOURCE BioLife Solutions, Inc.
FAQ
What is the date when BioLife Solutions plans to file its Form 10-K?
What led to the delay in the filing of BioLife Solutions' Form 10-K?
What does BioLife Solutions specialize in?
What is the stock symbol for BioLife Solutions?
